Merck licenses SciBrunch's KRAS G12D inhibitor SPR2015 in deal worth up to $2.13bn
Merck has secured worldwide rights to SciBrunch Therapeutics' preclinical KRAS G12D inhibitor SPR2015 in an oncology licensing agreement worth up to $2.13bn.
SciBrunch will receive $400m upfront, with additional development, regulatory and commercial milestones potentially taking aggregate consideration to $2.13bn.
The agreement gives Merck responsibility for the development, manufacturing and commercialisation of SPR2015 worldwide.
Field | Content |
Alert Type | Licensing agreement |
Companies | Merck; SciBrunch Therapeutics |
Deal Type | Exclusive global licence |
Asset or Company | SPR2015 |
Therapy Area(s) | Oncology |
Technology or Modality | Oral KRAS G12D ON inhibitor |
Deal Value | $400m upfront; aggregate potential consideration of up to $2.13bn |
Development Stage | Preclinical |
Geography | Worldwide |
What Happened | Merck entered an exclusive global licence agreement with SciBrunch Therapeutics for SPR2015, an investigational oral KRAS G12D ON inhibitor. |
Why It Matters | KRAS G12D is an important oncology target across multiple tumour types, and the agreement expands Merck's pipeline of investigational targeted cancer therapies. |
Supporting Context | SciBrunch will receive $400m upfront and is eligible for additional development, regulatory and commercial milestone payments that could bring aggregate consideration to $2.13bn. |
Strategic Rationale | The transaction gives Merck control of a preclinical targeted therapy designed to inhibit the active state of KRAS G12D. |
Potential Impact | SPR2015 could add another approach to targeting KRAS-driven cancers if it progresses successfully through clinical development. |
Key Takeaway | Merck is committing $400m upfront for worldwide rights to SPR2015, with the oncology licensing agreement potentially reaching $2.13bn. |
What to Watch | Progression of SPR2015 from preclinical development into human clinical trials. |
Primary Source | Merck |
Relevant Date | 28 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commentaires